A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Cystic fibrosis (CF) is a life-limiting disorder that is characterised by respiratory tract inflammation that is mediated by a range of microbial pathogens. Small colony variants (SCVs) of common respiratory pathogens are being increasingly recognised in CF. The aim of this systematic review is to investigate the prevalence of SCVs, clinical characteristics and health outcomes for patients with CF, and laboratory diagnostic features of SCVs compared to non-small colony variants (NCVs) for a range of Gram-positive and Gram-negative respiratory pathogens.
METHODS: A literature search was conducted (PubMed, Web of Science, Embase and Scopus) in April 2020 to identify articles of interest. Data pertaining to demographic characteristics of participants, diagnostic criteria of SCVs, SCV prevalence and impact on lung function were extracted from included studies for analysis.
RESULTS: Twenty-five of 673 studies were included in the systematic review. Individuals infected with SCVs of Staphylococcus aureus (S. aureus) were more likely to have had prior use of the broad-spectrum antibiotic trimethoprim sulfamethoxazole (p < 0.001), and the prevalence of SCVs in patients infected with S. aureus was estimated to be 19.3% (95% CI: 13.5% to 25.9%). Additionally, patients infected with SCVs of Gram-negative and Gram-positive pathogens were identified to have a lower forced expiratory volume in one second percentage predicted (-16.8, 95% CI: -23.2 to -10.4) than those infected by NCVs. Gram-positive SCVs were commonly described as small and non-haemolytic, grown on Mannitol salt or blood agar for 24 h at 35°C and confirmed using tube coagulase testing.
CONCLUSION: The findings of this systematic review demonstrate that SCVs of S. aureus have a high prevalence in the CF community, and that the occurrence of SCVs in Gram-positive and Gram-negative pathogens is linked to poorer respiratory function. Further investigation is necessary to determine the effect of infection by SCVs on the CF population.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC pulmonary medicine - 23(2023), 1 vom: 01. Sept., Seite 323 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ryan, Harrigan [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 04.09.2023 Date Revised 20.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12890-023-02611-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361560508 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM361560508 | ||
003 | DE-627 | ||
005 | 20231226085412.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12890-023-02611-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1205.xml |
035 | |a (DE-627)NLM361560508 | ||
035 | |a (NLM)37658311 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ryan, Harrigan |e verfasserin |4 aut | |
245 | 1 | 2 | |a A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.09.2023 | ||
500 | |a Date Revised 20.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
520 | |a BACKGROUND: Cystic fibrosis (CF) is a life-limiting disorder that is characterised by respiratory tract inflammation that is mediated by a range of microbial pathogens. Small colony variants (SCVs) of common respiratory pathogens are being increasingly recognised in CF. The aim of this systematic review is to investigate the prevalence of SCVs, clinical characteristics and health outcomes for patients with CF, and laboratory diagnostic features of SCVs compared to non-small colony variants (NCVs) for a range of Gram-positive and Gram-negative respiratory pathogens | ||
520 | |a METHODS: A literature search was conducted (PubMed, Web of Science, Embase and Scopus) in April 2020 to identify articles of interest. Data pertaining to demographic characteristics of participants, diagnostic criteria of SCVs, SCV prevalence and impact on lung function were extracted from included studies for analysis | ||
520 | |a RESULTS: Twenty-five of 673 studies were included in the systematic review. Individuals infected with SCVs of Staphylococcus aureus (S. aureus) were more likely to have had prior use of the broad-spectrum antibiotic trimethoprim sulfamethoxazole (p < 0.001), and the prevalence of SCVs in patients infected with S. aureus was estimated to be 19.3% (95% CI: 13.5% to 25.9%). Additionally, patients infected with SCVs of Gram-negative and Gram-positive pathogens were identified to have a lower forced expiratory volume in one second percentage predicted (-16.8, 95% CI: -23.2 to -10.4) than those infected by NCVs. Gram-positive SCVs were commonly described as small and non-haemolytic, grown on Mannitol salt or blood agar for 24 h at 35°C and confirmed using tube coagulase testing | ||
520 | |a CONCLUSION: The findings of this systematic review demonstrate that SCVs of S. aureus have a high prevalence in the CF community, and that the occurrence of SCVs in Gram-positive and Gram-negative pathogens is linked to poorer respiratory function. Further investigation is necessary to determine the effect of infection by SCVs on the CF population | ||
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Clinical impact | |
650 | 4 | |a Cystic fibrosis | |
650 | 4 | |a Prevalence | |
650 | 4 | |a Small colony variants | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a Culture Media |2 NLM | |
700 | 1 | |a Ballard, Emma |e verfasserin |4 aut | |
700 | 1 | |a Stockwell, Rebecca E |e verfasserin |4 aut | |
700 | 1 | |a Duplancic, Christine |e verfasserin |4 aut | |
700 | 1 | |a Thomson, Rachel M |e verfasserin |4 aut | |
700 | 1 | |a Smith, Kimberley |e verfasserin |4 aut | |
700 | 1 | |a Bell, Scott C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 23(2023), 1 vom: 01. Sept., Seite 323 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:01 |g month:09 |g pages:323 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-023-02611-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 01 |c 09 |h 323 |